GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Botanix Pharmaceuticals Ltd (ASX:BOT) » Definitions » EV-to-EBIT

Botanix Pharmaceuticals (ASX:BOT) EV-to-EBIT : -43.18 (As of May. 22, 2024)


View and export this data going back to 1985. Start your Free Trial

What is Botanix Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Botanix Pharmaceuticals's Enterprise Value is A$432.36 Mil. Botanix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.01 Mil. Therefore, Botanix Pharmaceuticals's EV-to-EBIT for today is -43.18.

The historical rank and industry rank for Botanix Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

ASX:BOT' s EV-to-EBIT Range Over the Past 10 Years
Min: -44.75   Med: 0   Max: 0
Current: -43.18

ASX:BOT's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 10.09 vs ASX:BOT: -43.18

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Botanix Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was A$275.64 Mil. Botanix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.01 Mil. Botanix Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3.63%.


Botanix Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Botanix Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Botanix Pharmaceuticals EV-to-EBIT Chart

Botanix Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.91 -0.88 -17.25 -3.68 -17.68

Botanix Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3.68 - -17.68 -

Competitive Comparison of Botanix Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Botanix Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Botanix Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Botanix Pharmaceuticals's EV-to-EBIT falls into.



Botanix Pharmaceuticals EV-to-EBIT Calculation

Botanix Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=432.355/-10.013
=-43.18

Botanix Pharmaceuticals's current Enterprise Value is A$432.36 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Botanix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Botanix Pharmaceuticals  (ASX:BOT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Botanix Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-10.013/275.6436
=-3.63 %

Botanix Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was A$275.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Botanix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Botanix Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Botanix Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Botanix Pharmaceuticals (ASX:BOT) Business Description

Traded in Other Exchanges
Address
661 Newcastle Street, D2, LEEDERVILLE, WA, AUS, 6007
Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

Botanix Pharmaceuticals (ASX:BOT) Headlines

No Headlines